Ethyl Pyruvate Inhibits Hypoxic Pulmonary Vasoconstriction and Attenuates Pulmonary Artery Cytokine Expression

Journal of Surgical Research

Volumn 145, Issue 1, 2008, Pages 130-134

  Tsai, Ben M ^a   Lahm, Tim ^a   Morrell, Eric D ^a   Crisostomo, Paul R ^a   Poynter, Jeffrey ^a   Wang, Meijing ^a   Meldrum, Daniel R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hypoxia; inflammation; pulmonary hypertension; signal transduction

Indexed keywords

ETHYL PYRUVIC ACID; INTERLEUKIN 1; MESSENGER RNA; PYRUVIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION; HYPOXIA; LUNG ARTERY; LUNG VASOCONSTRICTION; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANOXIA; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; INTERLEUKIN-1; LUNG; MALE; PULMONARY ARTERY; PYRUVATES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION;

EID: 38949159715     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.03.067     Document Type: Article

References (36)

1. Tsai B.M., Turrentine M.W., Sheridan B.C., et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression 81 (2006) 272
2. Tsai B.M., Wang M., Pitcher J.M., et al. Hypoxic pulmonary vasoconstriction and pulmonary artery tissue cytokine expression are mediated by protein kinase C. Am J Physiol Lung Cell Mol Physiol 287 (2004) L1215
3. Tsai B.M., Wang M., Turrentine M.W., et al. Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. Ann Thorac Surg 78 (2004) 360
4. Tsai B.M., Wang M., Pitcher J.M., et al. Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock 24 (2005) 417
5. Morrell E.D., Tsai B.M., Wang M., et al. p38 mitogen-activated protein kinase mediates the sustained phase of hypoxic pulmonary vasoconstriction and plays a role in phase I vasodilation. J Surg Res 134 (2006) 335
6. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol 274 (1998) R577
7. Wang M., Sankula R., Tsai B.M., et al. P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock 21 (2004) 170
8. Fink M.P. Ethyl pyruvate: a novel anti-inflammatory agent. Crit Care Med 31 Suppl (2003) S51
9. Fink M.P. Ringer's ethyl pyruvate solution: a novel resuscitation fluid for the treatment of hemorrhagic shock and sepsis. J Trauma 54 Suppl 5 (2003) S141
10. Fink M.P. Ethyl pyruvate: a novel treatment for sepsis and shock. Minerva Anesthesiol 70 (2004) 365
11. Sims C.A., Wattanasirichaigoon S., Menconi M.J., et al. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 29 (2001) 1513
12. Woo Y.J., Taylor M.D., Cohen J.E., et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg 127 (2004) 1262
13. Yang R., Gallo D.J., Baust J.J., et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 283 (2002) G212
14. Fullerton D.A., McIntyre Jr. R.C., Hahn A.R., et al. Dysfunction of cGMP-mediated pulmonary vasorelaxation in endotoxin-induced acute lung injury. Am J Physiol 268 (1995) L1029
15. Morrell E.D., Tsai B.M., Crisostomo P.R., et al. Therapeutic concepts for hypoxic pulmonary vasoconstriction involving ion regulation and the smooth muscle contractile apparatus. J Mol Cell Cardiol 40 (2006) 751
16. Fink M.P. Ringer's ethyl pyruvate solution: a novel resuscitation fluid. Minerva Anesthesiol 67 (2001) 190
17. Yang R., Uchiyama T., Alber S.M., et al. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med 32 (2004) 1453
18. Yang R., Uchiyama T., Watkins S.K., et al. Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock 22 (2004) 369
19. Venkataraman R., Kellum J.A., Song M., et al. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 18 (2002) 507
20. Salahudeen A.K., Clark E.C., and Nath K.A. Hydrogen peroxide-induced renal injury. A protective role for pyruvate in vitro and in vivo. J Clin Invest 88 (1991) 1886
21. Tawadrous Z.S., Delude R.L., and Fink M.P. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 17 (2002) 473
22. DeBoer L.W., Bekx P.A., Han L., et al. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol 265 (1993) H1571
23. Tsung A., Kaizu T., Nakao A., et al. Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation 79 (2005) 196
24. Hauser B., Kick J., Asfar P., et al. Ethyl pyruvate improves systemic and hepatosplanchnic hemodynamics and prevents lipid peroxidation in a porcine model of resuscitated hyperdynamic endotoxemia. Crit Care Med 33 (2005) 2034
25. Ulloa L., Ochani M., Yang H., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99 (2002) 12351
26. Rahman R., O'Rourke F., and Jungas R.L. Effects of insulin on CO2 fixation in adipose tissue. Evidence for regulation of pyruvate transport. J Biol Chem 258 (1983) 483
27. Ertel W., Morrison M.H., Ayala A., et al. Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. Am J Physiol 269 (1995) R160
28. Sheridan B.C., McIntyre Jr. R.C., Meldrum D.R., et al. Vinblastine attenuates endotoxin-induced impairment of CGMP-mediated pulmonary vasorelaxation. Shock 6 (1996) 35
29. Tamura D.Y., Moore E.E., Partrick D.A., et al. Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock 17 (2002) 269
30. Kisala J.M., Ayala A., Stephan R.N., et al. A model of pulmonary atelectasis in rats: activation of alveolar macrophage and cytokine release. Am J Physiol 264 (1993) R610
31. Johnson A., and Ferro T.J. TNF-alpha augments pulmonary vasoconstriction via the inhibition of nitrovasodilator activity. J Appl Physiol 73 (1992) 2483
32. Stevens T., Janssen P.L., and Tucker A. Acute and long-term TNF-alpha administration increases pulmonary vascular reactivity in isolated rat lungs. J Appl Physiol 73 (1992) 1992
33. Castaneda J., Isusi A., and Tamayo L. Hypoxic pulmonary vasoconstriction increases during endotoxemia in the perfused rat lung. J Trauma 50 (2001) 882
34. Liu S.F., Dewar A., Crawley D.E., et al. Effect of tumor necrosis factor on hypoxic pulmonary vasoconstriction. J Appl Physiol 72 (1992) 1044
35. Ziesche R., Petkov V., Williams J., et al. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue. Proc Natl Acad Sci USA 93 (1996) 12478
36. Han Y., Englert J.A., Yang R., et al. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther 312 (2005) 1097